These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15245790)

  • 1. APOE promoter polymorphisms and dementia in the elderly.
    Lambert JC; Berr C; Cottel D; Amouyel P; Helbecque N
    Neurosci Lett; 2004 Jul; 365(2):116-9. PubMed ID: 15245790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of APOE epsilon2/epsilon3/epsilon4 and promoter gene variants with dementia but not cardiovascular mortality in old age.
    Heijmans BT; Slagboom PE; Gussekloo J; Droog S; Lagaay AM; Kluft C; Knook DL; Westendorp RG
    Am J Med Genet; 2002 Jan; 107(3):201-8. PubMed ID: 11807900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haplogroup analysis of the risk associated with APOE promoter polymorphisms (-219T/G, -491A/T and -427T/C) in Colombian Alzheimer's disease patients.
    Parra-Bonilla G; Arboleda G; Yunis J; Solano E; Pardo R; Arango G; Hedmont D; Arboleda H
    Neurosci Lett; 2003 Oct; 349(3):159-62. PubMed ID: 12951193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APOE and APOC1 promoter polymorphisms and the risk of Alzheimer disease in African American and Caribbean Hispanic individuals.
    Tycko B; Lee JH; Ciappa A; Saxena A; Li CM; Feng L; Arriaga A; Stern Y; Lantigua R; Shachter N; Mayeux R
    Arch Neurol; 2004 Sep; 61(9):1434-9. PubMed ID: 15364690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The algorithm for Alzheimer risk assessment based on APOE promoter polymorphisms.
    Limon-Sztencel A; Lipska-Ziętkiewicz BS; Chmara M; Wasag B; Bidzan L; Godlewska BR; Limon J
    Alzheimers Res Ther; 2016 May; 8(1):19. PubMed ID: 27193889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of APOE promoter but not A2M polymorphisms with risk of developing Alzheimer's disease.
    Halimi G; Duplan L; Bideau C; Iniesta D; Berthézène P; Oddoze C; Verdier JM; Michel B; Bergé-Lefranc JL
    Neuroreport; 2000 Nov; 11(16):3599-601. PubMed ID: 11095526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promoter polymorphism (-491A/T) in the APOE gene of Finnish Alzheimer's disease patients and control individuals.
    Helisalmi S; Hiltunen M; Valonen P; Mannermaa A; Koivisto AM; Lehtovirta M; Ryynänen M; Soininen H
    J Neurol; 1999 Sep; 246(9):821-4. PubMed ID: 10525981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ApoE -491A/T promoter polymorphism is not an independent risk factor, but associated with the epsilon4 allele in Hungarian Alzheimer's dementia population.
    Juhász A; Palotás A; Janka Z; Rimanóczy A; Palotás M; Bódi N; Boda K; Zana M; Vincze G; Kálmán J
    Neurochem Res; 2005 May; 30(5):591-6. PubMed ID: 16176061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The -491A/T apolipoprotein E promoter polymorphism association with Alzheimer's disease: independent risk and linkage disequilibrium with the known APOE polymorphism.
    Town T; Paris D; Fallin D; Duara R; Barker W; Gold M; Crawford F; Mullan M
    Neurosci Lett; 1998 Aug; 252(2):95-8. PubMed ID: 9756330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein E promoter polymorphisms (-491A/T and -427T/C) and Alzheimer's disease: no evidence of association in the Irish population.
    Lynch CA; Brazil J; Cullen B; Coakley D; Gill M; Lawlor BA; Hawi Z
    Ir J Med Sci; 2008 Mar; 177(1):29-33. PubMed ID: 18057979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between ε2/3/4, promoter polymorphism (-491A/T, -427T/C, and -219T/G) at the apolipoprotein E gene, and mental retardation in children from an iodine deficiency area, China.
    Li J; Zhang F; Wang Y; Wang Y; Qin W; Xing Q; Qian X; Guo T; Gao X; He L; Gao J
    Biomed Res Int; 2014; 2014():236702. PubMed ID: 24790992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia.
    Bullido MJ; Artiga MJ; Recuero M; Sastre I; García MA; Aldudo J; Lendon C; Han SW; Morris JC; Frank A; Vázquez J; Goate A; Valdivieso F
    Nat Genet; 1998 Jan; 18(1):69-71. PubMed ID: 9425904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allelic expression of APOE in human brain: effects of epsilon status and promoter haplotypes.
    Bray NJ; Jehu L; Moskvina V; Buxbaum JD; Dracheva S; Haroutunian V; Williams J; Buckland PR; Owen MJ; O'Donovan MC
    Hum Mol Genet; 2004 Nov; 13(22):2885-92. PubMed ID: 15385439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APOE genotype-function relationship: evidence of -491 A/T promoter polymorphism modifying transcription control but not type 2 diabetes risk.
    Geng H; Law PP; Ng MC; Li T; Liang LY; Ge TF; Wong KB; Liang C; Ma RC; So WY; Chan JC; Ho YY
    PLoS One; 2011; 6(10):e24669. PubMed ID: 22028770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphisms in the apolipoprotein E (APOE) gene in gerontopsychiatric patients.
    Zill P; Engel R; Hampel H; Behrens S; Bürger K; Padberg F; Stübner S; Möller HJ; Ackenheil M; Bondy B
    Eur Arch Psychiatry Clin Neurosci; 2001; 251(1):24-8. PubMed ID: 11315514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions of functional apolipoprotein E gene promoter polymorphisms with smoking on aortic atherosclerosis.
    Viiri LE; Viiri KM; Ilveskoski E; Huhtala H; Mäki M; Tienari PJ; Perola M; Lehtimäki T; Karhunen PJ
    Circ Cardiovasc Genet; 2008 Dec; 1(2):107-16. PubMed ID: 20031552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms of the human apolipoprotein E promoter and bleomycin hydrolase gene: risk factors for Alzheimer's dementia?
    Thome J; Gewirtz JC; Sakai N; Zachariou V; Retz-Junginger P; Retz W; Duman RS; Rösler M
    Neurosci Lett; 1999 Oct; 274(1):37-40. PubMed ID: 10530514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of APOE genotype and promoter polymorphism on risk of Alzheimer's disease.
    Wang JC; Kwon JM; Shah P; Morris JC; Goate A
    Neurology; 2000 Dec; 55(11):1644-9. PubMed ID: 11113217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of APOE promoter polymorphisms to Alzheimer's disease risk.
    Lambert JC; Araria-Goumidi L; Myllykangas L; Ellis C; Wang JC; Bullido MJ; Harris JM; Artiga MJ; Hernandez D; Kwon JM; Frigard B; Petersen RC; Cumming AM; Pasquier F; Sastre I; Tienari PJ; Frank A; Sulkava R; Morris JC; St Clair D; Mann DM; Wavrant-DeVrièze F; Ezquerra-Trabalon M; Amouyel P; Hardy J; Haltia M; Valdivieso F; Goate AM; Pérez-Tur J; Lendon CL; Chartier-Harlin MC
    Neurology; 2002 Jul; 59(1):59-66. PubMed ID: 12105308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Independent association of an APOE gene promoter polymorphism with increased risk of myocardial infarction and decreased APOE plasma concentrations-the ECTIM study.
    Lambert JC; Brousseau T; Defosse V; Evans A; Arveiler D; Ruidavets JB; Haas B; Cambou JP; Luc G; Ducimetière P; Cambien F; Chartier-Harlin MC; Amouyel P
    Hum Mol Genet; 2000 Jan; 9(1):57-61. PubMed ID: 10587578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.